Trial Profile
A multiple-dose phase I study of MepiGel in healthy volunteers
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2015
Price :
$35
*
At a glance
- Drugs Mepivacaine (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions
- 06 Feb 2015 New trial record
- 04 Feb 2015 Relmada Therapeutics plans to initiate this study with the selected MepiGel formulations later this year. The data from these studies will inform the design of a subsequent Phase 2 proof of concept study in patients suffering from neuropathic pain.